Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A17 in advanced solid tumors
NCT06512116Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIBP-A17 in breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 5 more, sponsored by Shanghai Institute of Biological Products. Primary endpoints: Dose Limiting Toxicity at 126 days, Maximum Tolerated Dose at 260 days and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
SIBP-A17
03
Conditions
breast cancergastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06512116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512116.